We provide you with 20 years of free, institutional-grade data for GRTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GRTX. Explore the full financial landscape of GRTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Galera Therapeutics, Inc(NASDAQ:GRTX) 
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimet...
Website: http://www.galeratx.com
Full Time Employees: 32
CEO: J. Mel Sorensen
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about GRTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.